Economics: Costs, Cost-Effectiveness, Budget Impact, and Benefits of HIV Treatment and Prevention

Since 2005, our team has collected and analyzed primary, patient-level data to estimate the costs, cost-effectiveness, affordability and benefits of ART and related interventions in a range of countries and settings. Since then, results have been published of the cost of treatment per patient served, cost-effectiveness of different adult and pediatric treatment delivery models and drug regimens, and anticipated costs of changing treatment guidelines and numbers of patients served. Further analysis of large patient-level data sets and mathematical modeling have helped to translate these findings to national scale. This work has helped program managers and policy makers to understand the current costs of the HIV response, evaluate the economic implications of proposed guideline changes, allocate resources more efficiently, and advocate for greater resource mobilization.

Follow the links below for more information about the projects, publications, and investigators involved.

• Laboratory optimization
• Behavioral economics and preferences
• HIV testing
• Costs, resource allocation, and budget impact
• Costs of pre-exposure prophylaxis (PrEP)